Collegium Pharmaceutical, Inc. (COLL) financial statements (2021 and earlier)

Company profile

Business Address 100 TECHNOLOGY CENTER DRIVE
STOUGHTON, MA 02072
State of Incorp. VA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments174165146116170154149
Cash and cash equivalents174165146116170154149
Receivables83768185738481
Inventory, net of allowances, customer advances and progress billings1617191610910
Inventory1617191610910
Prepaid expense3   1  
Other current assets0   0  
Other undisclosed current assets1356235
Total current assets:278262251224256250245
Noncurrent Assets
Operating lease, right-of-use asset89999910
Property, plant and equipment19181513121210
Intangible assets, net (including goodwill), including:336353369386303337
Intangible assets, net (excluding goodwill)336353369386   
Other undisclosed intangible assets, net (including goodwill)    303337
Restricted cash and investments3333   
Other noncurrent assets0000000
Total noncurrent assets:366382396411515457
TOTAL ASSETS:644644647635306304302
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities35243325403335
Accounts payable1068661211
Accrued liabilities25182519332125
Debt47474848443
Other undisclosed current liabilities157171171172158165158
Total current liabilities:239242252244202201196
Noncurrent Liabilities
Long-term debt and lease obligation218229239249171819
Long-term debt, excluding current maturities2102202302408910
Operating lease, liability999991010
Other undisclosed noncurrent liabilities(9)(9)     
Total noncurrent liabilities:210229239249171819
Total liabilities:458471491494219220216
Stockholders' equity
Stockholders' equity attributable to parent186173156141878486
Common stock0000000
Additional paid in capital519513507500447442437
Accumulated deficit(333)(340)(351)(359)(360)(358)(352)
Total stockholders' equity:186173156141878486
TOTAL LIABILITIES AND EQUITY:644644647635306304302

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues76797877747375
Cost of revenue
(Cost of Goods and Services Sold)
(32)(31)(30)(38)(49)(47)(49)
Gross profit:44484839252626
Operating expenses(29)(29)(32)(34)(27)(33)(31)
Operating income (loss):1520175(2)(6)(5)
Nonoperating income
(Investment Income, Nonoperating)
0000001
Interest and debt expense(8)(8)(8)(5)(0)(0)(0)
Income (loss) from continuing operations before income taxes:71280(2)(6)(5)
Income tax expense(0)(0)(0)    
Net income (loss) available to common stockholders, diluted:71180(2)(6)(5)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):71180(2)(6)(5)
Comprehensive income (loss), net of tax, attributable to parent:71180(2)(6)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: